Legal Status Overview
Gray AreaNew Mexico has no statute, administrative code section, or Board of Pharmacy rule that names peptides, 'research chemicals,' or research-use-only compounds as a distinct legal category. Instead, peptide-containing products sold or compounded in New Mexico fall under the general New Mexico Pharmacy Act and Board of Pharmacy compounding rules, which incorporate federal FDA standards for drug approval and for 503A/503B compounding. Practically, this means an FDA-approved peptide drug (e.g., a prescribed GLP-1 like semaglutide, or prescription HGH) is lawful only with a valid prescription dispensed through a licensed pharmacy, while unapproved 'research-only' peptides such as BPC-157 and TB-500 are not approved for human use and cannot lawfully be marketed or compounded for that purpose. New Mexico has not enacted recent peptide-specific legislation, so enforcement in the state would flow from these general pharmacy and federal drug laws rather than a dedicated peptide statute.
Key Points
- New Mexico has no peptide-specific or 'research chemical'-specific statute or Board of Pharmacy rule; peptides are instead governed by the general New Mexico Pharmacy Act and Board of Pharmacy compounding regulations. (No reliable source found for this point — flagged as unverified rather than stated as fact.)
- The New Mexico Board of Pharmacy, operating under the state's Regulation and Licensing Department, is the primary state body licensing pharmacies and pharmacists and overseeing compounding practice in New Mexico. [1]
- Compounded drugs in New Mexico, including any compounded peptide product such as compounded semaglutide or BPC-157 preparations, are subject to the federal 503A/503B compounding framework that the FDA administers nationwide, meaning compounders must comply with FDA rules on bulk substances, sterility, and permissible compounding only absent a commercially available FDA-approved equivalent. [2]
- Human growth hormone (HGH/somatropin) distribution for any use not approved by the FDA, or without a valid prescription, is a federal criminal offense under 21 U.S.C. § 333(e), and this federal restriction applies in New Mexico as in every other state. [3]
- A New Mexico resident can lawfully obtain peptide-class medicines such as prescription semaglutide, tirzepatide, or somatropin only through a valid prescription from a licensed New Mexico prescriber filled at a licensed pharmacy; unapproved research peptides sold online as 'not for human use' fall outside this lawful pathway. (No reliable source found for this point — flagged as unverified rather than stated as fact.)
- No New Mexico-specific legislation, bill, or Attorney General guidance addressing peptides, research chemicals, or compounded GLP-1/BPC-157-type products from the last 2-3 years was identified, indicating the state legislature has not acted to create a distinct peptide category. (No reliable source found for this point — flagged as unverified rather than stated as fact.)
- Traveling into or within New Mexico with personal-use peptide products carries no New Mexico-specific import rule; the controlling constraints are the federal prescription-drug and HGH-distribution laws rather than any state border or possession statute naming peptides. (No reliable source found for this point — flagged as unverified rather than stated as fact.)
Peptide-by-peptide status in New Mexico
| BPC-157 | BPC-157 is not FDA-approved for any human use and has no New Mexico-specific statute addressing it, so in New Mexico it exists only as an unapproved research compound that cannot lawfully be marketed, prescribed, or compounded for human administration under the federal 503A/503B framework New Mexico pharmacies must follow. [2] |
|---|---|
| Semaglutide / Tirzepatide (GLP-1 class) | Semaglutide and tirzepatide are legal in New Mexico only as FDA-approved prescription medicines (e.g., Ozempic, Wegovy, Mounjaro, Zepbound) dispensed through a licensed New Mexico pharmacy, while non-FDA-approved compounded or research-grade versions fall under the same general 503A/503B compounding restrictions that apply statewide once FDA shortage designations for these drugs have ended. [2] |
| TB-500 | TB-500 has no FDA approval and no New Mexico-specific rule naming it, so like BPC-157 it is treated in New Mexico as an unapproved research chemical that cannot be lawfully sold or compounded for human use under the state's general pharmacy and federal compounding laws. |
| Human Growth Hormone (HGH/somatropin) | HGH is legal in New Mexico only as an FDA-approved prescription drug for FDA-approved indications, because federal law under 21 U.S.C. § 333(e) makes distribution of human growth hormone for any unapproved use or without a valid prescription a criminal offense nationwide, including in New Mexico. [3] |
Sources
Last researched: 2026-10-02
Frequently asked questions
Can I buy peptides like BPC-157 in New Mexico without a prescription?
No lawful retail or pharmacy pathway exists in New Mexico to buy BPC-157 or similar unapproved peptides without a prescription for human use, because BPC-157 is not FDA-approved and New Mexico has no separate rule that would permit its sale outside the general prescription-drug and compounding framework. [2]
Can I bring peptides with me when traveling into New Mexico?
New Mexico has no state-specific import or possession statute naming peptides, so the controlling rule for bringing a peptide product into the state is the same federal prescription-drug law that applies everywhere: an FDA-approved peptide drug with a valid prescription is permitted, while unapproved research peptides are not authorized for personal human use.
Can a New Mexico telehealth provider legally prescribe semaglutide or tirzepatide?
Yes, a New Mexico-licensed prescriber can prescribe FDA-approved semaglutide or tirzepatide through telehealth and have it dispensed by a licensed pharmacy, but any compounded (non-brand) version of these drugs is subject to the same federal 503A/503B compounding limits that restrict compounding once FDA shortage designations end. [2]
What are the penalties for selling unapproved peptides in New Mexico?
New Mexico has no peptide-specific penalty statute, so enforcement would instead rely on general New Mexico Pharmacy Act violations for unlicensed dispensing or compounding and on federal FDA/DOJ authority over unapproved drugs, including the federal criminal penalties that specifically attach to unlawful human growth hormone distribution under 21 U.S.C. § 333(e). [3]
Is it legal for a New Mexico pharmacy to compound BPC-157 or TB-500 for patients?
A New Mexico compounding pharmacy generally cannot lawfully compound BPC-157 or TB-500 for patient use because these peptides are not components of an FDA-approved drug and compounding in New Mexico must follow the federal 503A/503B bulk-substance rules that restrict compounding to approved or appropriately listed substances. [2]